Citalopram, QTc Prolongation, and Torsades de Pointes

Psychosomatics

Volumn 56, Issue 1, 2015, Pages 36-43

  Tampi, Rajesh R ^a   Balderas, Michael ^b   Carter, Kathleen V ^b   Tampi, Deena J ^c   Moca, Marian ^a   Knudsen, Amy ^a   May, Jacquelyn ^a  

^a University of Texas Health Science Center at San Antonio   (United States)

^b UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^c SAINT FRANCIS HOSPITAL AND MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CITALOPRAM; SEROTONIN UPTAKE INHIBITOR;

ARTICLE; BRADYCARDIA; CARDIOVASCULAR RISK; COMORBIDITY; CORRELATION ANALYSIS; DEPRESSION; DISEASE ASSOCIATION; DISEASE COURSE; DRUG OVERDOSE; DRUG USE; HEART VENTRICLE FIBRILLATION; HUMAN; HYPERTENSION; LONG QT SYNDROME; MENTAL DISEASE; META ANALYSIS (TOPIC); QT PROLONGATION; QTC PROLONGATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); SUPRAVENTRICULAR TACHYCARDIA; SYSTEMATIC REVIEW; TORSADE DES POINTES; CHEMICALLY INDUCED; ELECTROCARDIOGRAPHY;

CITALOPRAM; ELECTROCARDIOGRAPHY; HUMANS; LONG QT SYNDROME; SEROTONIN UPTAKE INHIBITORS; TORSADES DE POINTES;

EID: 84921521940     PISSN: 00333182     EISSN: 15457206     Source Type: Journal    
DOI: 10.1016/j.psym.2014.09.002     Document Type: Review

References (41)

1. Apler A. Citalopram for major depressive disorder in adults: a systematic review and meta-analysis of published placebo-controlled trials. BMJ Open 2011, 1(2):e000106. 10.1136/bmjopen-2011-000106.
2. Seitz D.P., Gill S.S., Conn D.K. Citalopram versus other antidepressants for late-life depression: a systematic review and meta-analysis. Int J Geriatr Psychiatry 2010, 25(12):1296-1305.
3. FDA Drug Safety Communication: Revised recommendations for Celexa (citalopram hydrobromide) related to a potential risk of abnormal heart rhythms with high doses. Available from: Accessed July 26, 2014. http://www.fda.gov/Drugs/DrugSafety/ucm297391.htm.
4. MHRA Drug Safety Update: Citalopram and escitalopram: QT interval prolongation-new maximum daily dose restrictions (including in elderly patients), contraindications, and warnings. Available from: Accessed July 26, 2014. http://www.mhra.gov.uk/Safetyinformation/DrugSafetyUpdate/CON137769.
5. Katz A.J., Dusetzina S.B., Farley J.F., et al. Distressing adverse events after antidepressant switch in the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) trial: influence of adverse events during initial treatment with citalopram on development of subsequent adverse events with an alternative antidepressant. Pharmacotherapy 2012, 32(3):234-243.
6. Siddique H., Hynan L.S., Weiner M.F. Effect of a serotonin reuptake inhibitor on irritability, apathy, and psychotic symptoms in patients with Alzheimer's disease. J Clin Psychiatry 2009, 70(6):915-918.
7. Vieweg W.V., Hasnain M., Howland R.H., et al. Citalopram, QTc interval prolongation, and torsade de pointes. How should we apply the recent FDA ruling?. Am J Med 2012, 125(9):859-868.
8. Funk K.A., Bostwick J.R. A comparison of the risk of QT prolongation among SSRIs. Ann Pharmacother 2013, 47(10):1330-1341.
9. Beach S.R., Celano C.M., Noseworthy P.A., et al. QTc prolongation, torsades de pointes, and psychotropic medications. Psychosomatics 2013, 54(1):1-13.
10. Kogut C., Crouse E.B., Vieweg W.V., et al. Selective serotonin reuptake inhibitors and torsade de pointes: new concepts and new directions derived from a systematic review of case reports. Ther Adv Drug Saf 2013, 4(5):189-198.
11. Naranjo C.A., Busto U., Sellers E.M., et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981, 30(2):239-245.
12. Favre M.P., Sztajzel J., Bertschy G. Bradycardia during citalopram treatment: a case report. Pharmacol Res 1999, 39(2):149-150.
13. Catalano G., Catalano M.C., Epstein M.A., Tsambiras P.E. QTc interval prolongation associated with citalopram overdose: a case report and literature review. Clin Neuropharmacol 2001, 24(3):158-162.
14. Meuleman C., Jourdain P., Bellorini M., et al. Citalopram and torsades de pointes. A case report. Arch Mal Coeur Vaiss 2001 Sep, 94(9):1021-1024.
15. Engebretsen K.M., Harris C.R., Wood J.E. Cardiotoxicity and late onset seizures with citalopram overdose. J Emerg Med 2003, 25(2):163-166.
16. Cuenca P.J., Holt K.R., Hoefle J.D. Seizure secondary to citalopram overdose. J Emerg Med 2004, 26(2):177-181.
17. Kourgiannidis G., Chierchia G.B., Wyffels E., Geelen P., Brugada P. A case of monomorphic ventricular tachycardia?. J Cardiovasc Electrophysiol 2005, 16(9):1014-1016.
18. Blaschke D., Parwani A.S., Huemer M., et al. Torsade de pointes during combined treatment with risperidone and citalopram. Pharmacopsychiatry 2007, 40(6):294-295.
19. Tarabar A.F., Hoffman R.S., Nelson L. Citalopram overdose: late presentation of torsades de pointes (TdP) with cardiac arrest. J Med Toxicol 2008, 4(2):101-105.
20. Venkatraman N., O'Neil D., Hall A.P. Life-threatening overdose with lamotrigine, citalopram, and chlorpheniramine. J Postgrad Med 2008, 54(4):316-317.
21. Kanjanauthai S., Kanluen T., Chareonthaitawee P. Citalopram induced torsade de pointes, a rare life threatening side effect. Int J Cardiol 2008, 131(1):e33-e34.
22. Bruggisser M., Rätz Bravo A., Bodmer M. Medication associated long QT syndrome. Praxis (Bern 1994) 2009, 98(24):1409-1415.
23. Digby G., Machaalany J., Malik P., et al. Multifactorial QT interval prolongation. Cardiol J 2010, 17(2):184-188.
24. Fayssoil A., Issi J., Guerbaa M., Raynaud J.C., Heroguelle V. Torsade de pointes induced by citalopram and amiodarone. Ann Cardiol Angeiol (Paris) 2011, 60(3):165-168.
25. de Gregorio C., Morabito G., Cerrito M., Dattilo G., Oreto G. Citalopram-induced long QT syndrome and torsade de pointes: role for concomitant therapy and disease. Int J Cardiol 2011, 148(2):226-228.
26. Liotier J., Coudoré F. Drug monitoring of a case of citalopram overdosage. Drug Chem Toxicol 2011, 34(4):420-423.
27. Deshmukh A., Ulveling K., Alla V., et al. Prolonged QTc interval and torsades de pointes induced by citalopram. Tex Heart Inst J 2012, 39(1):68-70.
28. Ibrahim M., Omar B. Ciprofloxacin-induced torsade de pointes. Ciprofloxacin-induced torsade de pointes. Am J Emerg Med 2012, 30(1):252. [e5-9].
29. Unterecker S., Warrings B., Deckert J., Pfuhlmann B. Correlation of QTc interval prolongation and serum level of citalopram after intoxication-a case report. Pharmacopsychiatry 2012, 45(1):30-34.
30. Roden D.M. Clinical practice. Long-QT syndrome. N Engl J Med 2008, 358(2):169-176.
31. Jimmink A., Caminada K., Hunfeld N.G., Touw D.J. Clinical toxicology of citalopram after acute intoxication with the sole drug or in combination with other drugs: overview of 26 cases. Ther Drug Monit 2008, 30(3):365-371.
32. Witchel H.J., Pabbathi V.K., Hofmann G., et al. Inhibitory actions of the selective serotonin re-uptake inhibitor citalopram on HERG and ventricular l-type calcium currents. FEBS Lett 2002, 512(1-3):59-66.
33. Rasmussen S.L., Overø K.F., Tanghøj P. Cardiac safety of citalopram: prospective trials and retrospective analyses. J Clin Psychopharmacol 1999, 19(5):407-415.
34. Personne M., Sjöberg G., Persson H. Citalopram overdose-review of cases treated in Swedish hospitals. J Toxicol Clin Toxicol 1997, 35(3):237-240.
35. Kelly C.A., Dhaun N., Laing W.J., et al. Comparative toxicity of citalopram and the newer antidepressants after overdose. J Toxicol Clin Toxicol 2004, 42(1):67-71.
36. Aström-Lilja C., Odeberg J.M., Ekman E., Hägg S. Drug-induced torsades de pointes: a review of the Swedish pharmacovigilance database. Pharmacoepidemiol Drug Saf 2008, 17(6):587-592.
37. Castro V.M., Clements C.C., Murphy S.N., et al. QT interval and antidepressant use: a cross sectional study of electronic health records. Br Med J 2013, 346:f288.
38. Zivin K., Pfeiffer P.N., Bohnert A.S., et al. Evaluation of the FDA warning against prescribing citalopram at doses exceeding 40mg. Am J Psychiatry 2013, 170(6):642-650.
39. Beach S.R., Kostis W.J., Celano C.M., et al. Meta-analysis of selective serotonin reuptake inhibitor-associated QTc prolongation. J Clin Psychiatry 2014, 75(5):e441-e449.
40. Porsteinsson A.P., Drye L.T., Pollock B.G., et al. Effect of citalopram on agitation in Alzheimer disease: the CitAD randomized clinical trial. J Am Med Assoc 2014, 311(7):682-691.
41. Ryysy R., Sinisalo J., Viitasalo M. Citalopram overdose poisoning in QTc interval prolongation. Duodecim 2006, 122(1):97-102.